Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738939) titled 'IKS04 Regimen in Advanced Solid Tumors That Express CA242' on July 23.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Iksuda Therapeutics Ltd.
Condition:
Colorectal Cancer
Gastro Esophageal Junctional Cancer
Gastric Cancer (GC)
GEJ Adenocarcinoma
PDAC - Pancreatic Ductal Adenocarcinoma
Biliary Tract Cancer (BTC)
Gall Bladder Cancer
Cholangiocarcinoma
Intervention:
Drug: IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
Recruitment Status: Not recruiting
Phase...